GABA: Difference between revisions
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Notjusttired (talk | contribs) m (layout, refs, fix link) |
Notjusttired (talk | contribs) m (Text replacement - "u| first" to "u | first") |
||
| (36 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Cleanup/Citations needed|date=Dec 2019|reason=No references}} | {{Cleanup/Citations needed | date = Dec 2019|reason=No references}} | ||
'''Gamma aminobutyric acid''' (GABA), is a [[neurotransmitter]] made from the [[:Category:Amino acids|amino acid]] [[glutamate]]. GABA is the chief inhibiting, or calming [[neurotransmitter]] in the [[brain]], functioning as a brake on the neural circuitry during [[stress]]. Low GABA levels are associated with [[restlessness]], [[anxiety]], [[insomnia]] and a low mood/[[depression]]. GABA works to balance [[glutamate]] (excitatory) in the brain. GABA is the brake pedal on a car while glutamate is the gas pedal.{{citation needed}} | '''Gamma aminobutyric acid''' (GABA), is a [[neurotransmitter]] made from the [[:Category:Amino acids|amino acid]] [[glutamate]]. GABA is the chief inhibiting, or calming [[neurotransmitter]] in the [[brain]], functioning as a brake on the neural circuitry during [[stress]]. Low GABA levels are associated with [[restlessness]], [[anxiety]], [[insomnia]] and a low mood/[[depression]]. GABA works to balance [[glutamate]] (excitatory) in the brain. GABA is the brake pedal on a car while glutamate is the gas pedal.{{citation needed}} | ||
| Line 11: | Line 11: | ||
*[[zinc]] | *[[zinc]] | ||
*[[Omega 3 fatty acid]], and | *[[Omega 3 fatty acid]], and | ||
*[[inositol]]{{citation needed|date=September 2020}} | *[[inositol]]{{citation needed | date = September 2020}} | ||
==Notable studies== | ==Notable studies== | ||
*2005, [https://www.ncbi.nlm.nih.gov/pubmed/15757488 GABA and glutamate systems as therapeutic targets in depression and mood disorders] | *2005, [https://www.ncbi.nlm.nih.gov/pubmed/15757488 GABA and glutamate systems as therapeutic targets in depression and mood disorders]<ref>{{Cite journal | last = Kendell | first = Steven F. | author-link = | last2 = Krystal | first2 = John H. | authorlink2 = | last3 = Sanacora | first3 = Gerrard | authorlink3 = | date = February 2005 | title = GABA and glutamate systems as therapeutic targets in depression and mood disorders| url = https://www.ncbi.nlm.nih.gov/pubmed/15757488|journal=Expert Opinion on Therapeutic Targets|volume=9|issue=1| pages=153–168|doi=10.1517/14728222.9.1.153|issn=1744-7631|pmc=|pmid=15757488|access-date=|quote=|via=}}</ref> | ||
*2005, [https://www.ncbi.nlm.nih.gov/pubmed/16400244 Beyond monoamines: glutamatergic function in mood disorders] | *2005, [https://www.ncbi.nlm.nih.gov/pubmed/16400244 Beyond monoamines: glutamatergic function in mood disorders]<ref>{{Cite journal | last = Kugaya | first = Akira | author-link = | last2 = Sanacora | first2 = Gerard | authorlink2 = | date = Oct 2005 | title = Beyond monoamines: glutamatergic function in mood disorders| url = https://www.ncbi.nlm.nih.gov/pubmed/16400244|journal=CNS spectrums|volume=10|issue=10 | pages = 808–819|doi=10.1017/s1092852900010403|issn=1092-8529|pmc=|pmid=16400244|access-date=|quote=|via=}}</ref> | ||
*2006, [https://www.ncbi.nlm.nih.gov/pubmed/16971751 Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans]<ref name=pmid16971751>{{ | *2006, [https://www.ncbi.nlm.nih.gov/pubmed/16971751 Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans]<ref name="pmid16971751">{{Cite journal | last = Abdou | first = Adham M. | last2 = Higashiguchi | first2 = S. | last3 = Horie | first3 = K. | last4 = Kim | first4 = Mujo | last5 = Hatta | first5 = H. | last6 = Yokogoshi | first6 = H. | date = 2006 | title=Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans| url = https://pubmed.ncbi.nlm.nih.gov/16971751/|journal=BioFactors (Oxford, England)|volume=26|issue=3 | pages = 201–208|doi=10.1002/biof.5520260305|issn=0951-6433|pmid=16971751}}</ref> | ||
*2007, Thorne Research, Inc: Gamma-Aminobutyric Acid (GABA). Alternative Medicine Review, 2007; 12(3) | *2007, Thorne Research, Inc: Gamma-Aminobutyric Acid (GABA). Alternative Medicine Review, 2007; 12(3) | ||
| Line 29: | Line 29: | ||
[[Category:Neurotransmitters]] | [[Category:Neurotransmitters]] | ||
[[Category:Amino acids]] | [[Category:Amino acids]] | ||
[[Category:Depression alternative treatments]] | |||
[[Category:Depression treatments]] | |||
Latest revision as of 22:49, May 18, 2023
 | This article needs cleanup to meet MEpedia's guidelines. The reason given is: This page needs additional references or sources for verification - multiple references need to be added. (Dec 2019) |
Gamma aminobutyric acid (GABA), is a neurotransmitter made from the amino acid glutamate. GABA is the chief inhibiting, or calming neurotransmitter in the brain, functioning as a brake on the neural circuitry during stress. Low GABA levels are associated with restlessness, anxiety, insomnia and a low mood/depression. GABA works to balance glutamate (excitatory) in the brain. GABA is the brake pedal on a car while glutamate is the gas pedal.[citation needed]
Supplements to support GABA and glutamate are:
- amino acids GABA
- L-theanine
- N-acetyl-cysteine (NAC)
- vitamin B6
- vitamin D
- magnesium
- zinc
- Omega 3 fatty acid, and
- inositol[citation needed]
Notable studies[edit | edit source]
- 2005, GABA and glutamate systems as therapeutic targets in depression and mood disorders[1]
- 2005, Beyond monoamines: glutamatergic function in mood disorders[2]
- 2006, Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans[3]
- 2007, Thorne Research, Inc: Gamma-Aminobutyric Acid (GABA). Alternative Medicine Review, 2007; 12(3)
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- ↑ Kendell, Steven F.; Krystal, John H.; Sanacora, Gerrard (February 2005). "GABA and glutamate systems as therapeutic targets in depression and mood disorders". Expert Opinion on Therapeutic Targets. 9 (1): 153–168. doi:10.1517/14728222.9.1.153. ISSN 1744-7631. PMID 15757488.
- ↑ Kugaya, Akira; Sanacora, Gerard (October 2005). "Beyond monoamines: glutamatergic function in mood disorders". CNS spectrums. 10 (10): 808–819. doi:10.1017/s1092852900010403. ISSN 1092-8529. PMID 16400244.
- ↑ Abdou, Adham M.; Higashiguchi, S.; Horie, K.; Kim, Mujo; Hatta, H.; Yokogoshi, H. (2006). "Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans". BioFactors (Oxford, England). 26 (3): 201–208. doi:10.1002/biof.5520260305. ISSN 0951-6433. PMID 16971751.
